The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients
Open accessAbstract
BACKGROUND & AIMS: To elucidate the survival of the patients with unresectable hepatocellular carcinoma (HCC) who underwent transcatheter arterial lipiodol chemoembolization (TACE) and to analyze the factors affecting the survivals. METHODS: During the last 8 years, a nationwide prospective cohort study was performed in 8510 patients with unresectable HCC who underwent TACE using emulsion of lipiodol and anticancer agents followed by gelatin sponge particles as an initial treatment. Exclusion criteria were extrahepatic metastases and/or any previous treatment prior to the present TACE. The primary end point was survival. The survival rates were calculated by the Kaplan-Meier method. The multivariate analyses for the factors affecting survival were evaluated by the Cox proportional hazard model. The mean follow-up period was 1.77 years. RESULTS: For overall survival rates by TACE, median and 1-, 3-, 5-, and 7-year survivals were 34 months, 82%, 47%, 26%, and 16%, respectively. Both the degree of liver damage and the tumor-node-metastasis (TNM) system proposed by the Liver Cancer Study Group of Japan demonstrated good stratification of survivals (P = .0001). The multivariate analyses showed significant difference in degree of liver damage (P = .0001), alpha-fetoprotein value (P = .0001), maximum tumor size (P = .0001), number of lesions (P = .0001), and portal vein invasion (P = .0001). The last 3 factors could be replaced by TNM stage. The TACE-related mortality rate after the initial therapy was .5%. CONCLUSIONS: TACE showed safe therapeutic modality with a 5-year survival of 26% for unresectable HCC patients. The degrees of liver damage, TNM stage, and alpha-fetoprotein values were independent risk factors for patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
Self-citationThe general rules for the clinical and pathological study of primary liver cancer
Liver Cancer Study Group of Japan (1989) · The Japanese Journal of Surgery · doi:10.1007/bf02471576 · Cited by 1,037
(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Arii, S., Yamaoka, Y., Futagawa, S., Inoue, K., Kobayashi, K., Kojiro, M., Makuuchi, M., Nakamura, Y., Okita, K., & Yamada, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20456 · Cited by 725
Self-citationSimplified Staging for Hepatocellular Carcinoma
Vauthey, J. N., Lauwers, G. Y., Esnaola, N. F., Do, K.-A., Belghiti, J., Mirza, N., Curley, S. A., Ellis, L. M., Regimbeau, J.-M., Rashid, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1527 · Cited by 700
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Hepatocellular carcinoma: a review
Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,185
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V., Miller, F. H., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.006 · Cited by 1,074
Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update
Vivarelli, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i42.7316 · Cited by 799
Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., Asaoka, Y., Sato, T., Masuzaki, R., Kondo, Y., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.425 · Cited by 724
Self-citationEpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q., Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L.-X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6013 · Cited by 717
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Self-citationRaoul, J.-L., Sangro, B., Forner, A., Mazzaferro, V., Piscaglia, F., Bolondi, L., & Lencioni, R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.006 · Cited by 537
Peng, Z.-W., Zhang, Y.-J., Chen, M.-S., Xu, L., Liang, H.-H., Lin, X.-J., Guo, R.-P., Zhang, Y.-Q., & Lau, W. Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9936 · Cited by 531
Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.044 · Cited by 491
Self-citationBurrel, M., Reig, M., Forner, A., Barrufet, M., Lope, C. R. D., Tremosini, S., Ayuso, C., Llovet, J. M., Real, M. I., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.008 · Cited by 485
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Hepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors
Uchino, K., Tateishi, R., Shiina, S., Kanda, M., Masuzaki, R., Kondo, Y., Goto, T., Omata, M., Yoshida, H., & Koike, K. (2011) · Cancer · doi:10.1002/cncr.25960 · Cited by 427
Self-citationReport of the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan†
Ikai, I., Arii, S., Okazaki, M., Okita, K., Omata, M., Kojiro, M., Takayasu, K., Nakanuma, Y., Makuuchi, M., Matsuyama, Y., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00119.x · Cited by 412
Self-citationLiu, C.-Y., Chen, K.-F., & Chen, P.-J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021535 · Cited by 391
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Kadalayil, L., Benini, R., Pallan, L., O'Beirne, J., Marelli, L., Yu, D., Hackshaw, A., Fox, R., Johnson, P., Burroughs, A. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt247 · Cited by 370
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Yin, L., Li, H., Li, A.-J., Lau, W. Y., Pan, Z.-Y., Lai, E. C. H., Wu, M.-C., & Zhou, W.-P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.012 · Cited by 334
Hiraoka, A., Michitaka, K., Kumada, T., Izumi, N., Kadoya, M., Kokudo, N., Kubo, S., Matsuyama, Y., Nakashima, O., Sakamoto, M., et al. (2017) · Liver Cancer · doi:10.1159/000479984 · Cited by 331
Self-citationLuo, J., Guo, R.-P., Lai, E. C. H., Zhang, Y.-J., Lau, W. Y., Chen, M.-S., & Shi, M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1321-8 · Cited by 328
Practice guidelines for management of hepatocellular carcinoma 2009
Korean Liver Cancer Study Group and National Cancer Center, K. (2009) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2009.15.3.391 · Cited by 257
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)
Kudo, M., Izumi, N., Kokudo, N., Sakamoto, M., Shiina, S., Takayama, T., Tateishi, R., Nakashima, O., Murakami, T., Matsuyama, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13675 · Cited by 83
Self-citationClinical Aspects of Liver Transplantation
Mangus, R. S., & Tector, A. J. (2011) · Practical Hepatic Pathology: A Diagnostic Approach · doi:10.1016/b978-0-443-06803-4.00041-1 · Cited by 1
Metadata
- Authors
- Takayasu, K., Arii, S., Ikai, I., Omata, M., Okita, K., Ichida, T., Matsuyama, Y., Nakanuma, Y., Kojiro, M., Makuuchi, M., & Yamaoka, Y.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 131
- Issue
- 2
- Pages
- 461-469
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2022138851
- Cited by
- 810
- References
- 27
- FWCI
- 23.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.